Pharmacokinetic	O
-	O
pharmacodynamic	O
analysis	O
.	O

The	O
mean	O
(	O
90	O
%	O
CI	O
)	O
slope	O
estimate	O
from	O
the	O
linezolid	O
concentration	O
-	O
R	O
-	O
R	O
interval	O
analysis	O
was	O
-	O
0	O
.	O
0017	O
(	O
-	O
0	O
.	O
0022	O
to	O
-	O
0	O
.	O
0011	O
)	O
ms	O
/	O
ng	O
/	O
ml	O
.	O

This	O
translates	O
to	O
mean	O
(	O
90	O
%	O
CI	O
)	O
predicted	O
decreases	O
in	O
heart	B-Organ
rate	O
of	O
approximately	O
1	O
.	O
5	O
(	O
1	O
.	O
0	O
to	O
2	O
.	O
0	O
)	O
and	O
3	O
.	O
0	O
(	O
2	O
.	O
1	O
to	O
4	O
.	O
1	O
)	O
beats	O
/	O
min	O
at	O
the	O
mean	O
Cmax	O
following	O
the	O
administration	O
of	O
600	O
-	O
and	O
1	O
,	O
200	O
-	O
mg	O
linezolid	O
doses	O
,	O
respectively	O
.	O

The	O
study	O
-	O
specific	O
mean	O
correction	O
factor	O
estimated	O
from	O
baseline	O
data	O
was	O
0	O
.	O
278	O
,	O
which	O
is	O
slightly	O
less	O
than	O
Fridericia	O
'	O
s	O
correction	O
(	O
0	O
.	O
333	O
)	O
.	O

Evaluation	O
of	O
the	O
various	O
correction	O
factors	O
showed	O
that	O
QTcF	O
most	O
appropriately	O
resolves	O
the	O
relationship	O
between	O
the	O
QT	O
interval	O
and	O
the	O
heart	B-Organ
rate	O
in	O
the	O
baseline	O
data	O
from	O
the	O
present	O
study	O
.	O

This	O
is	O
evident	O
upon	O
inspection	O
of	O
Fig	O
.	O

4	O
,	O
since	O
the	O
slope	O
between	O
the	O
QTcF	O
interval	O
and	O
the	O
R	O
-	O
R	O
interval	O
is	O
closest	O
to	O
zero	O
when	O
this	O
correction	O
is	O
applied	O
.	O

Fig	O
.	O

4	O
.	O

Evaluation	O
of	O
various	O
heart	B-Organ
rate	O
correction	O
factors	O
for	O
the	O
QT	O
interval	O
versus	O
the	O
R	O
-	O
R	O
interval	O
.	O

The	O
predicted	O
line	O
in	O
each	O
figure	O
represents	O
the	O
fit	O
from	O
a	O
linear	O
mixed	O
-	O
effect	O
model	O
with	O
R	O
-	O
R	O
interval	O
as	O
a	O
fixed	O
effect	O
and	O
subject	O
-	O
specific	O
random	O
effects	O
for	O
intercept	O
and	O
slope	O
.	O

The	O
results	O
from	O
the	O
concentration	O
-	O
QTcF	O
analysis	O
are	O
graphically	O
depicted	O
in	O
Fig	O
.	O

5	O
.	O

The	O
mean	O
(	O
90	O
%	O
CI	O
)	O
slope	O
estimate	O
from	O
the	O
linezolid	O
concentration	O
-	O
QTcF	O
analysis	O
was	O
-	O
0	O
.	O
0145	O
(	O
-	O
0	O
.	O
0768	O
to	O
0	O
.	O
0477	O
)	O
ms	O
/	O
mug	O
/	O
ml	O
.	O

At	O
the	O
geometric	O
mean	O
Cmax	O
following	O
the	O
infusion	O
of	O
linezolid	O
at	O
600	O
mg	O
(	O
14	O
.	O
9	O
mug	O
/	O
ml	O
)	O
and	O
1	O
,	O
200	O
mg	O
(	O
30	O
.	O
5	O
mug	O
/	O
ml	O
)	O
,	O
the	O
mean	O
(	O
90	O
%	O
CI	O
)	O
predicted	O
placebo	O
-	O
adjusted	O
changes	O
from	O
the	O
baseline	O
QTcF	O
were	O
-	O
0	O
.	O
217	O
(	O
-	O
1	O
.	O
14	O
to	O
0	O
.	O
710	O
)	O
and	O
-	O
0	O
.	O
444	O
(	O
-	O
2	O
.	O
34	O
to	O
1	O
.	O
45	O
)	O
ms	O
,	O
respectively	O
,	O
thus	O
confirming	O
a	O
lack	O
of	O
a	O
relationship	O
between	O
linezolid	O
concentrations	O
and	O
QTc	O
interval	O
.	O

Fig	O
.	O

5	O
.	O

QTcF	O
interval	O
versus	O
plasma	B-Organism_substance
linezolid	O
concentrations	O
.	O

